B7 costimulatory molecules play an important role in T-cell activation. It is well known that tumor cells that express B7 molecules can elicit antitumor immunity, but little is known regarding which B7 molecule, B7-1 (CD80) or B7-2 (CD86), can do so more efficiently. To address this issue, we have introduced B7-1 or B7-2 into 8709 cells, a radiation-induced mouse myelocytic leukemic cell line, and have compared their potentials regarding the induction of antitumor immunity. Either B7-1-or B7-2-transduced monoclonal sublines, 8709/B7-1 or 8709/B7-2, respectively, diminished tumorigenicity in syngeneic C3H mice. Some reports have indicated that B7-1 is superior to B7-2 in the induction of antitumor immunity. Contrary to these results, the 8709/B7-2 lines are superior to the 8709/B7-1 lines in their capacity to induce antitumor immunity. In vivo depletion of lymphocyte subsets demonstrated that both CD4 ϩ and CD8 ϩ T cells were indispensable for B7-1-or B7-2-dependent antitumor immunity, whereas natural killer cells were not. These results suggest that in some circumstances, B7-2 molecule is more effective than B7-1 molecule in eliciting antitumor immunity. Cancer Gene Therapy (2000) 7, 144 -150
R ecently immunotherapy against cancer has been revealed to be a hopeful therapeutic modality. One of the reasons is the advance in understanding the mechanism of T-cell activation. Activation of T cells is known to require at least two signals. The first one is an antigen (Ag)-specific signal that is provided when the T-cell receptor interacts with Ag presented in the context of major histocompatibility complex (MHC) on Ag-presenting cells (APCs). The second one is an Agindependent costimulatory signal. The T-cell costimulatory signal determines whether a T cell results in functional activation or clonal anergy state. 1, 2 The major costimulatory molecules that have been identified thus far are B7-1 and B7-2. Both B7-1 and B7-2 are members of the immunoglobulin superfamily [3] [4] [5] and are expressed on the cell surface of professional APCs such as activated B cells, monocytes, and dendritic cells. They deliver an important costimulatory signal via binding to their receptor, CD28, and an immunosuppressive signal via cytotoxic T lymphocyte (CTL) Ag-4 (CTLA)-4. 6 In animal tumor models, a number of approaches that introduce B7-1 gene into tumor cells succeeded in inducing antitumor immunity by CTLs 7, 8 and/or natural killer (NK) cells. 9 Then Yang et al 10 demonstrated that the B7-2 molecule could also induce antitumor immunity. We should consider which B7 molecule is better at inducing antitumor immunity when B7-mediated immunogene therapy is applied to cancer treatment. There are some reports comparing the potencies of the B7-1 and B7-2 molecules, but these potencies have not yet been determined. [11] [12] [13] In this paper, we have used a the 8709 cell line, which is a nonimmunogenic mouse myelocytic leukemia cell line, and introduced B7-1 or a B7-2 molecules into the leukemia cells to investigate the relative contribution of B7-1 and B7-2 in generating antitumor immunity. As a result, we found that either B7-1-or B7-2-transfected cells could elicit anti-leukemia immunity; we also found that B7-2-transfected cells were superior to B7-1-transfected cells in the induction of anti-leukemia immunity.
MATERIALS AND METHODS

Animals
C3H/HeN mice (H-2
k ) (Crea Japan) and BALB/c nu/nu mice were obtained at 6 weeks after birth and maintained in a specific pathogen-free animal facility at the University of Tokyo. Studies were started at 6 -10 weeks after birth. All experiments included 5-10 animals, and all the results were drawn from at least two independent experiments. In some experiments, peripheral blood was collected by retro-orbital sinus puncture.
Plasmid constructions
A DNA fragment encoding the entire coding frame of mouse B7-1 was generated by reverse transcriptase polymerase chain reaction according to the published sequence. 4 The polymerase chain reaction product was subcloned into pBluescript II (Stratagene, La Jolla, Calif), and its nucleotide sequence was verified by the dideoxy chain-terminal method with a Thermo Sequenase Kit (Amersham Pharmacia Biotech, Tokyo, Japan). The cloned B7-1 was then subcloned into pSR␣MSVneo, a mouse MPSV-based retroviral vector, 14 generating pmB7-1. A DNA fragment encoding the entire coding frame of mouse B7-2 was obtained from Dr. Azuma (National Childrens' Medical Research Center, Tokyo, Japan); this fragment was subcloned into pSR␣MSVneo, generating pmB7-2.
Cell lines
COS-7 cells were maintained in RPMI 1640 medium containing 10% fetal calf sera. The 8709 (H-2 k ) cell line, 15 which was established from radiation-induced myelocytic leukemia in the C3H mouse, was obtained from Dr. Yoshida (National Institute of Radiological Sciences, Chiba, Japan). The 8709 cells and its sublines were cultured at 37°C, 5% CO 2 in RPMI 1640 medium containing 10% fetal calf sera, 2 mM glutamine, and 100 ng/mL penicillin-streptomycin.
Retroviral preparation and infection of 8709 cells
Recombinant retrovirus was generated as described previously. 14 Briefly, the pmB7-1 and pmB7-2 plasmids and the mock plasmid (vector only) as a control were transfected with pSV--EMLV by the diethylaminoethyl-dextran method into COS-7 cells, and virus supernatant produced by COS-7 cells was used to infect 8709 cells in the presence of 8 g/mL of Polybrene (Sigma, St. Louis, Mo). After infection, the 8709 cells were selected with G418 (300 g/mL) (Sigma), and polyclonal 8709/B7-1, 8709/B7-2, and 8709/MOCK cells were obtained. Monoclonal 8709/B7-1-and 8709/B7-2-derived cells were cloned by limiting dilution. All of the sublines used in this study were independent and were maintained in vitro for no longer than 14 days before in vivo experiments. Medium from 8709/B7-1, 8709/B7-2, and 8709/MOCK cells was confirmed to be helper virus-free by demonstrating a lack of serial transfer of neo r from transduced to uninfected NIH-3T3 cells. 
Flow cytometric analysis
CD4
ϩ or CD8 ϩ T-cell or NK cell depletion studies
The hybridoma-producing rat anti-mouse CD4 monoclonal Ab (mAb) GK1.5 and the rat anti-mouse CD8 mAb 53-6.7 were injected into pristane-treated BALB/c nu/nu mice. Ascites containing mAb were precipitated by ammonium sulfate and resuspended by PBS. Next, they were dialyzed in PBS for 24 hours and purified using MabTrap GII (Pharmacia, Uppsala, Sweden). For the T-cell depletion experiments, each mouse received 0.3 mg of purified mAb intraperitoneally (i.p.) on days Ϫ7 and 1 as well as 0.2 mg on day 7 from the day of tumor injection. The spleen was examined by flow cytometry using rat anti-mouse RM4-5 (anti-CD4) conjugated to fluorescein isothiocyanate (PharMingen) and rat anti-mouse Lyt2.2 (anti-CD8) conjugated to fluorescein isothiocyanate (PharMingen). For the NK cell depletion experiments, mice were injected with rabbit anti-asialo GM 1 anti-sera (Wako Chemicals, Osaka, Japan). Briefly, freeze-dried anti-sera were dissolved in 1 mL of water and diluted 1/10 in PBS; a total of 0.2 mL of this solution was given i.p. on days Ϫ7, 1, and 7 from the day of tumor injection. NK depletion was examined by NK assay of the spleen. 16 Briefly, spleen cells obtained from the mice injected with anti-asialo GM 1 were used as effector cells. Remaining NK activities were tested in vitro using 51 Cr-labeled YAC-1 cells as a target. Assays were done twice in triplicate. The effector to target ratios were 100:1, 50:1, 25:1, and 12.5:1. The percentage of specific lysis was calculated according to the following formula:
Animal studies
Cells were washed twice in Hank's balanced saline solution (HBSS) (Life Technologies, Gaithersburg, Md) before injection. Trypan blue-resistant cells were counted, suspended to the appropriate concentrations, and injected i.p. in 0.2 mL of HBSS. In some experiments, cells were first irradiated at 3500 rad (1 rad ϭ 0.01 Gy) from a 137 Cs source discharging 160 rad/minute and then counted using trypan blue staining. This dose of radiation was selected based on pilot studies clarifying that 3000 rad was the minimum dose required to stop proliferation and prevent outgrowth in vitro. Moreover, mice injected with 5 ϫ 10 5 of 3500 rad-irradiated 8709 cells did not develop leukemia. These results indicate that irradiation of 8709 cells at 3500 rad is sufficient to eliminate their proliferative activity.
Statistical analysis
Survival time was measured from the day of injection, based on the endpoint of day 300, when surviving mice were sacrificed. The survival distributions were compared using log rank tests, and a P value of Ͻ.05 was considered to be significant.
RESULTS
Transduction of mouse B7-1 and B7-2 into 8709 cells
The parental cell line used in this study is 8709, a radiation-induced myelocytic leukemic cell line derived from a C3H (H-2 k ) mouse. The 8709 cells express a medium level of MHC class I (H-2K k and a dim level of H-2D k ) but lack MHC class II (I-A k , I-E k ), B7-1, B7-2, and ICAM-1. The clones introduced with B7-1, B7-2, and a mock vector were obtained as described in Materials and Methods and were screened by flow cytometry for expression of B7-1, B7-2, and MHC class I. More than 30 clones were obtained from each of the 8709/B7-1 and 8709/B7-2 polyclonal pools. The subclones expressing B7-1 and B7-2 at a high level, respectively, were chosen (8709/B7-1/clone 10, hereafter 8709/B7-1, and 8709/B7-2/clone 16, hereafter 8709/B7-2) and were used in all in vivo experiments. Equivalent results were obtained using a second set of clones, 8709/B7-1/clone 6, in which the expression level of B7-1 was one-half of a log lower than that of 8709/B7-1/clone 10 and 8709/B7-2/ clone 7, in which the expression level of B7-2 was similar to that of 8709/B7-2/clone 16 (data not shown).
Tumorigenicity of 8709 cells in syngeneic C3H mice Mice were injected i.p. with different amounts of wildtype (WT) 8709 cells (hereafter 8709/WT), and their survival was measured. Both groups of mice injected with 5 ϫ 10 5 to 5 ϫ 10 4 cells developed massive ascites and died within 10 weeks (Fig 1A) . In the dead mice, peripheral blood and bone marrow were disseminated with blasts and spleens were massively enlarged.
To confirm that the monoclonal B7-transduced 8709 cells were still as tumorigenic as the WT cells, we studied the tumorigenicity of the B7-transduced 8709 cells in vitro and in vivo.
To study in vitro cell growth, cell suspensions (8709/ WT, 8709/MOCK, 8709/B7-1, and 8709/B7-2 cells) starting at 1 ϫ 10 5 cells were grown, and the number of viable cells was counted daily for 4 days. There were no significant differences among the 8709/WT, 8709/ MOCK, 8709/B7-1, and 8709/B7-2 cells (Fig 1B) .
To study in vivo tumorigenicity, BALB/c nu/nu mice were injected with B7-transfected 8709 cells. Groups of six nude mice were injected i.p. with 5 ϫ 10 5 cells and their survival was followed. There were no significant differences among the 8709/WT, 8709/MOCK, 8709/ B7-1, and 8709/B7-2 cells, and all mice died within 6 weeks (Fig 1C) .
B7-2 is superior to B7-1 in induction of antitumor immunity following primary challenge in syngeneic mice To examine the tumorigenicity of the B7-transduced 8709 cells, we injected C3H mice with 5 ϫ 10 5 monoclonal B7-transduced or 8709/MOCK cells i.p. Although all of the mice died of leukemia, the median survival of the mice injected with the 8709/B7-1 cells was longer than that of the mice injected with the 8709/WT cells (median survival of 85 days versus 48 days, respectively, for 8709/B7-1 and 8709/WT; P ϭ .0088). In the 8709/ B7-2 cells, 17-33% of injected mice survived with a median survival of Ͼ128 days. Mice that survived were sacrificed on day 300, and no abnormalities were found. In the mice that were administered 8709/MOCK cells, a median survival of 50 days was noted, which was not significantly different from the survival of the mice that were administered 8709/WT cells (P ϭ .7533) (Fig 2) .
Prolonged survival of mice receiving 8709/B7 cells is mediated by both CD4 ϩ and CD8 ϩ T cells, but not by NK cells Mice were injected i.p. with either anti-CD4 Ab, anti-CD8 Ab, anti-NK Ab, or HBSS (as a control) three times on days Ϫ7, 1, and 7 as described in Materials and Methods. Peripheral lymphocytes from the mice were collected on days 7 and 14. We confirmed that Ͼ98% of either CD4 ϩ or CD8 ϩ T cells were depleted by mAb staining. NK cells were evaluated by NK assay as described in Materials and Methods. The percentage of specific lysis of NK-sensitive YAC-1 cells by mononuclear cells obtained from the NK-depleted mice spleen was Ͻ1% compared with 25% by the mononuclear cells obtained from the control mice spleen at an effector to target ratio of 50:1 (data not shown). An total of 5 ϫ 10 5 8709/B7 cells were injected i.p. on day 0. All mice undergoing either CD4 ϩ or CD8 ϩ depletion died of massive ascites within 9 weeks, when injected with the 8709/B7-1 cells. However, mice that received anti-NK Ab injections with subsequent challenge of the 8709/ B7-1 cells showed prolonged survival, as did the control mice injected with the same cells (Fig 3A) . We obtained very similar results with the 8709/B7-2 cells, as shown in Figure 3B . These results indicate that both CD4 ϩ and CD8 ϩ T cells were required, although NK cells were not (Fig  4) . We increased the vaccination dose to 5 ϫ 10, 6 but no effect was observed (data not shown). We also increased the number of vaccination times to three times, but we were unable to observe a result showing that the vaccination significantly affected the survival (data not shown).
DISCUSSION
Many investigators reported that in the induction of antitumor immunity, B7-1 was more potent than B7-2 as a costimulatory molecule; 11, 12 as far as we know, there has only been one report describing that B7-2 is more effective than B7-1. 13 In this study, we have compared the ability to induce antitumor immunity between the B7-1 and B7-2 costimulatory molecules to give better insight into the previous reports. In our experiments, we used a radiation-induced mouse myelocytic leukemia cell line, 8709. Our results showed that both B7-1-and B7-2-transduced 8709 cells prolonged the survival of the injected mice compared with the parental cells and that the effect was more prominent in B7-2-transduced 8709 cells. B7 molecules activate T cells via CD28 receptors but inhibit the activation of T cells via CTLA-4 receptors. 17 There was a report that B7-1 and B7-2 displayed similar avidity for CD28 and that both displayed higher avidity for CTLA-4, although B7-2 binding to CTLA-4 displayed more rapid dissociation kinetics than B7-1.
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There is also the possibility that the expression level of B7 molecules in relation to 8709/B7-1 or 8709/B7-2 cells causes the different results. However, in our study, as mentioned in Results, we examined (using a second set of clones) 8709/B7-1/clone 6, in which the expression level of B7-1 was one-half of a log lower than that of 8709/B7-1/clone 10; equivalent results were obtained. Thus, we believe that the expression level of the B7 molecules did not affect the results of our comparison between B7-1 and B7-2. The immunogenicity of the 8709 cells seemed to be weak because the injection of irradiated 8709 cells could not diminish the tumorigenicity of the subsequent challenge of the parental 8709 cells. Using weakly immunogenic TS/A adenocarcinoma cells or B16.F1 melanoma cells, Martin-Fontecha et al 13 showed that B7-2 was more efficient than B7-1 in the induction of antitumor immunity. They hypothesized that when tumor immunogenicity is very weak, B7-2 could provide a more efficient costimulation than B7-1. Thus, our data may support their hypothesis. However, our model might not be the best to compare B7-1 and B7-2, because our result is based on the tumor growth inhibition but not on the vaccine effect. It is possible that the outcome could be different in another model. We do not know the mechanism that would explain the difference in the immunity provided by B7-1 and B7-2. One possibility is that B7-2 is more efficient than B7-1 in the induction of CTLs. Another possibility is that the characteristics of the induced CTLs, such as cytokine production or cytolytic activities, are different. Interestingly, Kuchroo et al 19 and Lenschow et al 20 have reported evidence that an isolated blockade of B7-1 or B7-2 affects the type of immune response that develops by altering the differentiation of helper T cells. Eck et al 21 reported that B7-1 molecules down-regulate the expression of CD28 receptors, whereas the same effect is low for B7-2. Therefore, when performing immunogene therapy, it may be necessary to determine which B7 molecule is to be used under a given circumstance.
Next, we examined the role of lymphocyte subsets in the induction of antitumor immunity. In general, the antitumor immunity of B7-1-transduced tumors was mediated by CD8 ϩ T cells 7, 8 but some investigators have reported that there are systems in which CD4
ϩ T cells and CD8 ϩ T cells are both needed. Li et al 22 reported that both T cells were required for the B7-1-mediated rejection of melanoma cell lines. We also reported previously that both T cells were required for the B7-1-mediated rejection of M1 cells, a myelocytic leukemia cell line. 23 In this study, as shown above, both CD4 ϩ and CD8 ϩ T cells were required for the prolonged survival of the mice receiving B7-1-or B7-2-transduced 8709 cells. Because the 8709 cells express class I (H-2K k ) molecules but lack detectable levels of class II (I-A k /I-E k ) molecules on their surface, they can directly present tumor Ags through the class I but not class II molecules. It is likely that the B7-transduced 8709 cells activate CD8 ϩ T cells, which recognize tumor Ags presented by the class I molecules on the 8709 cells, as well as CD4 ϩ T cells, which recognize tumor Ags that have been released from the 8709 cells, taken up by dedicated APCs, proceeded into peptides, and presented by their class II molecules. Huang et al 24 reported that although B7-1-transduced tumor vaccines result in some degree of direct presentation to CD8 ϩ T cells, the dominant mechanism of CTL priming is through the uptake and presentation of tumor Ags by host APCs. We suppose that when immunogenicity is weak or absent, both CD4 ϩ and CD8 ϩ T cells are likely to be indispensable for B7-mediated antitumor immunity. Mouse NK cells reportedly express CD28, and thus have the ability to participate in the antitumor immunity. 9, 25, 26 In our systems, however, NK cells did not play an important role in antitumor immunity. This may arise from different conditions such as the expression level of MHC class I on the tumor cells or the sensitivity of tumor cells against NK cells.
It is controversial whether irradiated, nonproliferating B7-transduced leukemic cells can elicit protective immunity. Matulonis et al 27 reported that multiple injections of irradiated, nonproliferating B7-1-transduced leukemia cells, 32Dp210 cells, which were derived from 32Dcl3 and transformed with p210 bcr/abl , could not induce anti-leukemia immunity, although a single injection of live, proliferative cells could. On the contrary, it was reported that irradiated, nonproliferating B7-1-transduced acute myelocytic leukemic cells could elicit protective and therapeutic immunity through a single injection. 28 Our previous data also showed that a nonimmunogenic myelocytic leukemic cell line, M1, could elicit protective and therapeutic immunity through vaccination. 20 Our data in this report demonstrated that either irradiated B7-1-or B7-2-transduced 8709 cells cannot elicit protective immunity against leukemia cells, although we examined in several conditions. Determining the factors that could induce protective immunity by vaccination of irradiated cells is very important for clinical application. The immunogenicity must be one of the most important factors. 29 In the present system, the immunogenicity of the B7-transduced 8709 cells seemed to be so weak that it could not induce a full vaccination effect. If the 8709 cells have adequate tumor-associated Ags, additional expression of cytokines, costimulatory molecules, and/or adhesion molecules may potentiate the immunogenicity and induce protective immunity. Cavallo et al 30 reported that the simultaneous transduction of B7-1 and ICAM-1 into tumors induced antitumor immunity, whereas the transduction of B7-1 alone did not. We are currently evaluating the effect of ICAM-1 or interleukin-2 expression on 8709/B7 cells to generate a vaccination effect.
In conclusion, we demonstrated that in some circumstances B7-2 provides a more efficient costimulation than B7-1 with regard to the induction of antitumor immunity. However, the protective immunity could not be induced by vaccination of the B7-transduced tumor cells. However, to use B7-transduced tumor cells clinically, the protective and therapeutic immunity should be induced. Fortunately, human primary leukemic cells highly express class I and class II molecules and often express ICAM-1. 31 Thus, if the leukemia-associated Ags were presented adequately, anti-leukemia immunity could be induced. It is necessary, for cancer gene therapy to be successful, to know how to use the B7 molecules (B7-1 and B7-2) properly, and how to increase the total immunogenicity by transfecting fewer molecules.
